Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
In this study we have determined the incidence of hepatocellular carcinoma (HCC) development in primary biliary cirrhosis (PBC) and its effects on patient survival. Six hundred and sixty seven patients with liver histology compatible with or diagnostic of PBC were seen over a 20-year period. Two hundred and seventy three patients who had stage III or IV disease on their last biopsy and who had been followed up for at least 1 year following that biopsy (total follow-up with advanced disease 2,010 patient years) were identified (243 female, 30 male). Patients who developed HCC were identified and their confounding risk factors were excluded. Mayo risk scores were calculated for each clinic attendance and expected survival for each time point was compared with subsequent actual survival. Sixteen cases of HCC were seen in the patients with stage III or IV disease on last biopsy, providing an overall incidence of 5.9% in this group. Fourteen of these patients had died of HCC related causes, and 2 patients were alive at the census point. The incidence of HCC was significantly higher in males with stage III/IV disease than in females (20% vs. 4.1%, P < .005). Nine of one hundred and eight (8.3%) total female deaths in this group was attributable to HCC compared with 5 of 11 (45.5%, P < .05) male deaths. HCC was not seen in any of the 394 patients with stage I and II PBC followed-up over the same time period. Throughout the disease course of all PBC patients with HCC, the Mayo prognostic model over-predicted survival. Whereas it is a relatively rare complication of cirrhotic PBC in women, HCC is a relatively common cause of death in male PBC patients with cirrhosis. HCC typically develops several years after the onset of cirrhosis, and is poorly predicted by prognostic models. In view of these findings, consideration should be given to careful screening for HCC in male PBC patients with cirrhosis. The risk of HCC development may be an additional reason to consider earlier transplantation in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The incidence of HCC among patients with diagnosed PBC is estimated at 0.36 per 100 person years.Higher histological stage on liver biopsy denotes an increased risk for HCC in patients with PBC [249].A recent multicentre study from North America and Europe, based on prolonged observation of 4,565 patients with PBC, showed an incidence rate of 3.4 HCC cases for every 1,000 patient-years [8].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [249]
In the citing paper
“Surveillance with regular imaging was associated with better clinical outcome of PBC patients who develop HCC.(227)(228)(229)(230)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [227]
Citations
Cites
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Ikeda, K. (1993) · Hepatology · doi:10.1016/0270-9139(93)90505-h · Cited by 620
Symposium: Advances in Liver Pathology [Abridged]: Primary Biliary Cirrhosis
Scheuer, P. J. (1967) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576706001205 · Cited by 557
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
DI BISCEGLIE, A. M., RUSTGI, V. K., HOOFNAGLE, J. H., DUSHEIKO, G. M., & LOTZE, M. T. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-390 · Cited by 454
Nomura, F., Ohnishi, K., & Tanabe, Y. (1989) · Cancer · doi:10.1002/1097-0142(19891015)64:8<1700::aid-cncr2820640824>3.0.co;2-z · Cited by 305
Relationship Between Hepatocellular Carcinoma and Cirrhosis
Kew, M., & Popper, H. (1984) · Seminars in Liver Disease · doi:10.1055/s-2008-1040653 · Cited by 260
Cited by
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“with impaired prognosis [243,244].”
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citation(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
Management of primary biliary cirrhosis
Heathcote, J. E. (2000) · Hepatology · doi:10.1053/he.2000.5984 · Cited by 417
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Self-citationArguedas, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)06049-5 · Cited by 252
Impact of primary biliary cirrhosis on perceived quality of life: The UK-PBC national study
Mells, G. F., Pells, G., Newton, J. L., Bathgate, A. J., Burroughs, A. K., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Hepatology · doi:10.1002/hep.26365 · Cited by 227
Self-citationTarao, K., Nozaki, A., Ikeda, T., Sato, A., Komatsu, H., Komatsu, T., Taguri, M., & Tanaka, K. (2019) · Cancer Medicine · doi:10.1002/cam4.1998 · Cited by 205
Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis
Poupon, R. E., Bonnand, A.-M., Chrétien, Y., & Poupon, R. (1999) · Hepatology · doi:10.1002/hep.510290603 · Cited by 209
Yeoman, A. D., Al-Chalabi, T., Karani, J. B., Quaglia, A., Devlin, J., Mieli-Vergani, G., Bomford, A., O'Grady, J. G., Harrison, P. M., & Heneghan, M. A. (2008) · Hepatology · doi:10.1002/hep.22432 · Cited by 183
Trivedi, P. J., Lammers, W. J., van Buuren, H. R., Parés, A., Floreani, A., Janssen, H. L. A., Invernizzi, P., Battezzati, P. M., Ponsioen, C. Y., Corpechot, C., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308351 · Cited by 178
Hohenester, S., Oude-Elferink, R. P. J., & Beuers, U. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0164-5 · Cited by 179
Granito, A., Muratori, L., Lalanne, C., Quarneti, C., Ferri, S., Guidi, M., Lenzi, M., & Muratori, P. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i22.2994 · Cited by 172
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy
Purohit, T., & Cappell, M. S. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i7.926 · Cited by 138
Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis
Shibuya, A., Tanaka, K., Miyakawa, H., Shibata, M., Takatori, M., Sekiyama, K., Hashimoto, N., Amaki, S., Komatsu, T., & Morizane, T. (2002) · Hepatology · doi:10.1053/jhep.2002.33157 · Cited by 116
Caballería, L. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02258-4 · Cited by 114
Cavazza, A., Caballería, L., Floreani, A., Farinati, F., Bruguera, M., Caroli, D., & Parés, A. (2009) · Hepatology · doi:10.1002/hep.23095 · Cited by 114
Cirrhosis, W. S. (. V. F. C. P. G. F. P. B. (2014) · Hepatology Research · doi:10.1111/hepr.12270 · Cited by 124
Primary biliary cirrhosis—presentation and diagnosis
Leuschner, U. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00101-6 · Cited by 106
Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis
Jones, D. E., James, O. F., Portmann, B., Burt, A. D., Williams, R., & Hudson, M. (1999) · Hepatology · doi:10.1002/hep.510300103 · Cited by 103
Self-citationMotosugi, U., Ichikawa, T., Sano, K., Sou, H., Onohara, K., Muhi, A., Amemiya, F., Enomoto, N., Matsuda, M., Fujii, H., et al. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22630 · Cited by 100
Hepatocellular Carcinoma inAutoimmune Hepatitis
Park, S. Z., Nagorney, D. M., & Czaja, A. J. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005638500236 · Cited by 93
Jones, D. E., Al-Rifai, A., Frith, J., Patanwala, I., & Newton, J. L. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.026 · Cited by 91
Self-citationNatural history of primary biliary cirrhosis
Parés, A., & Rodés, J. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00100-4 · Cited by 89
“In the last decade, however, some reports have found that patients with PBC also develop hepatocellular carcinoma as seen in other chronic liver diseases, particularly those associated with ethanol abuse and HCV-related cirrhosis [64–68].”
BackgroundHarada, K., Hirohara, J., Ueno, Y., Nakano, T., Kakuda, Y., Tsubouchi, H., Ichida, T., & Nakanuma, Y. (2013) · Hepatology · doi:10.1002/hep.26176 · Cited by 87
Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis
Reshetnyak, V. I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i25.7683 · Cited by 86
Nissen, N. N., & Martin, P. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200211002-00003 · Cited by 77
Gossard, A. A., & Talwalkar, J. A. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.09.002 · Cited by 77
Plasma antioxidant levels in chronic cholestatic liver diseases
Floreani, Baragiotta, Martines, Naccarato, & D’Odorico (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00729.x · Cited by 74
Hepatic and Extrahepatic Malignancies in Primary Biliary Cirrhosis
Floreani, A., Baragiotta, A., Baldo, V., Menegon, T., Farinati, F., & Naccarato, R. (1999) · Hepatology · doi:10.1002/hep.510290501 · Cited by 74
Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Case Series
Wong, R. J., Gish, R. G., Frederick, R. T., Bzowej, N. H., & Frenette, C. T. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1444-6 · Cited by 75
Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis
Silveira, M. G., Suzuki, A., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22458 · Cited by 68
Cancer risk in primary biliary cirrhosis: a study in northern England
Howel, D., Metcalf, J. V., Gray, J., Newman, W. L., Jones, D. E. J., & James, O. F. W. (1999) · Gut · doi:10.1136/gut.45.5.756 · Cited by 67
Self-citationFibrotic Events in the Progression of Cholestatic Liver Disease
Wu, H., Chen, C., Ziani, S., Nelson, L. J., Avila, M. A., Nevzorova, Y. A., & Cubero, F. J. (2021) · Cells · doi:10.3390/cells10051107 · Cited by 65
Reduced heart rate variability and baroreflex sensitivity in primary biliary cirrhosis
Newton, J. L., Allen, J., Kerr, S., & Jones, D. E. J. (2006) · Liver International · doi:10.1111/j.1478-3231.2005.01214.x · Cited by 59
Self-citationGender specific medicine in liver diseases: A point of view
Durazzo, M., Belci, P., Collo, A., Prandi, V., Pistone, E., Martorana, M. C., Gambino, R., & Bo, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2127 · Cited by 63
Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis
Suzuki, A., Lymp, J., Donlinger, J., Mendes, F., Angulo, P., & Lindor, K. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.09.031 · Cited by 57
Review article: the modern management of autoimmune hepatitis
YEOMAN, A. D., Longhi, M. S., & Heneghan, M. A. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04241.x · Cited by 60
Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis
Deutsch, M., Papatheodoridis, G. V., Tzakou, A., & Hadziyannis, S. J. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282f163ed · Cited by 57
Predicting outcome in primary biliary cirrhosis
Lammers, W. J., Kowdley, K. V., & van Buuren, H. R. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30838-5 · Cited by 59
Nakanuma, Y., Zen, Y., & Portmann, B. C. (2012) · MacSween's Pathology of the Liver · doi:10.1016/b978-0-7020-3398-8.00010-6 · Cited by 56
Obeticholic acid for the treatment of primary biliary cholangitis
Ali, A. H., & Lindor, K. D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1218471 · Cited by 47
Natarajan, Y., Tansel, A., Patel, P., Emologu, K., Shukla, R., Qureshi, Z., El-Serag, H. B., Thrift, A. P., & Kanwal, F. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06498-7 · Cited by 49
“1 3 NOTE: Weights are from random effects analysis Overall (I-squared = 83.1%, p = 0.000) Hosonuma 2013 Trividi 2015 Kupier 2010 Su 2008 Jones 1997 Tomiyama 2013 Shibuya 2002 Nakamura 2007 Farinati 1994 Caturelli 2003 Study Findor 2002 15.70 (8.73, 28.24) 24.05 (9.67, 49.56) 6.76 (5.05, 8.87) 9.59…”
InfluentialHBV DNA integration and HBV‐transcript expression in non‐B, non‐C hepatocellular carcinoma in Japan
Tamori, A., Nishiguchi, S., Kubo, S., Narimatsu, T., Habu, D., Takeda, T., Hirohashi, K., & Shiomi, S. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10514 · Cited by 52
Kuiper, E. M. M., Hansen, B. E., Adang, R. P. R., van Nieuwkerk, C. M. J., Timmer, R., Drenth, J. P. H., Spoelstra, P., Brouwer, H. T., Kuyvenhoven, J. P. H., & van Buuren, H. R. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32834059e7 · Cited by 45
Primary Biliary Cholangitis: advances in management and treatment of the disease
Invernizzi, P., Floreani, A., Carbone, M., Marzioni, M., Craxì, A., Muratori, L., Gentilucci, U. V., Gardini, I., Gasbarrini, A., Kruger, P., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.05.001 · Cited by 48
Complications, symptoms, quality of life and pregnancy in cholestatic liver disease
Zakharia, K., Tabibian, A., Lindor, K. D., & Tabibian, J. H. (2018) · Liver International · doi:10.1111/liv.13591 · Cited by 42
Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development
Arsenijević, A., Stojanović, B., Milovanović, J., Arsenijević, D., Arsenijević, N., & Milovanović, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145097 · Cited by 42
Zhang, X.-X. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i12.3554 · Cited by 38
Mortality attributable to cholestatic liver disease in the United States†
Mendes, F. D., Kim, W. R., Pedersen, R. A., Therneau, T. M., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22178 · Cited by 41
MRI findings of primary biliary cirrhosis: correlation with Scheuer histologic staging
Kobayashi, S., Matsui, O., Gabata, T., Terayama, N., Sanada, J., Yamashiro, M., Minami, M., Kozaka, K., Harada, K., & Nakanuma, Y. (2004) · Abdominal Imaging · doi:10.1007/s00261-004-0228-x · Cited by 38
Battezzati, P. M., Zuin, M., Crosignani, A., Allocca, M., Invernizzi, P., Selmi, C., Villa, E., & Podda, M. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01018.x · Cited by 38
Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review
Toniutto, P., Shalaby, S., Mameli, L., Morisco, F., Gambato, M., Cossiga, V., Guarino, M., Marra, F., Brunetto, M. R., Burra, P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000277 · Cited by 41
Risk Factors and Prediction of Long-term Outcome in Primary Biliary Cirrhosis
Ishibashi, H., Komori, A., Shimoda, S., Ambrosini, Y. M., Gershwin, M. E., & Nakamura, M. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4462 · Cited by 42
Primary biliary cirrhosis: new perspectives in diagnosis and treatment
Prince, M. I., & Jones, D. E. J. (2000) · Postgraduate Medical Journal · doi:10.1136/pmj.76.894.199 · Cited by 37
Self-citationChronic Complications of Cholestasis
Assis, D. N. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.014 · Cited by 36
Ahn, J. C., & Flamm, S. L. (2004) · Disease-a-Month · doi:10.1016/j.disamonth.2004.10.001 · Cited by 36
Primary biliary cirrhosis: Evaluation with T2-weighted MR imaging and MR cholangiopancreatography
Haliloğlu, N. Ü., Erden, A., & Erden, İ. (2008) · European Journal of Radiology · doi:10.1016/j.ejrad.2007.11.003 · Cited by 35
Guidelines for Therapy of Autoimmune Liver Disease
Ishibashi, H., Komori, A., Shimoda, S., & Gershwin, M. E. (2007) · Seminars in Liver Disease · doi:10.1055/s-2007-979472 · Cited by 36
Tomiyama, Y., Takenaka, K., Kodama, T., Kawanaka, M., Sasaki, K., Nishina, S., Yoshioka, N., Hara, Y., & Hino, K. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0010 · Cited by 35
Tamori, A., Nishiguchi, S., Shiomi, S., Hayashi, T., Kobayashi, S., Habu, D., Takeda, T., Seki, S., Hirohashi, K., Tanaka, H., et al. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41914.x · Cited by 36
Primary biliary cirrhosis and hepatocellular carcinoma
Findor, J., He, X.-S., Sord, J., Terg, R., & Gershwin, M. E. (2002) · Autoimmunity Reviews · doi:10.1016/s1568-9972(02)00050-2 · Cited by 32
Hepatocellular Carcinoma in Primary Biliary Cholangitis
Sy, A. M., Ferreira, R., & John, B. V. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.011 · Cited by 33
Long-term Outcomes of Patients With Primary Biliary Cirrhosis and Hepatocellular Carcinoma
Imam, M. H., Silveira, M. G., Sinakos, E., Gossard, A. A., Jorgensen, R. A., Keach, J. C., DeCook, A. C., & Lindor, K. D. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.09.013 · Cited by 30
Floreani, A., Gabbia, D., & Martin, S. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042194 · Cited by 29
Wong, R. K. M., Lim, S. G., Wee, A., Chan, Y., Aung, M., & Wai, C. T. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05058.x · Cited by 26
Management of an Incidental Liver Mass
Boutros, C. N., Katz, S. C., & Espat, N. J. (2010) · Surgical Clinics of North America · doi:10.1016/j.suc.2010.04.005 · Cited by 25
Natural history of primary biliary cirrhosis
Abe, M., & Onji, M. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00351.x · Cited by 26
Malignancies in primary biliary cirrhosis
Piscaglia, F., & Sagrini, E. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282f16436 · Cited by 25
Identification of a secretory protein c19orf10 activated in hepatocellular carcinoma
Sunagozaka, H., Honda, M., Yamashita, T., Nishino, R., Takatori, H., Arai, K., Yamashita, T., Sakai, Y., & Kaneko, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25830 · Cited by 24
Extrahepatic Malignancies in Primary Biliary Cirrhosis: A Comparative Study at Two European Centers
Floreani, A., Spinazzè, A., Caballería, L., Reig, A., Cazzagon, N., Franceschet, I., Buja, A., Furlan, P., Harada, K., Leung, P. S. C., et al. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8446-7 · Cited by 24
Harada, K., & Nakanuma, Y. (2013) · Hepatology Research · doi:10.1111/hepr.12242 · Cited by 23
Murata, Y., Abe, M., Furukawa, S., Kumagi, T., Matsui, H., Matsuura, K., Matsuura, B., Hiasa, Y., & Onji, M. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-006-1914-y · Cited by 23
PRIMARY BILIARY CIRRHOSIS, PRIMARY SCLEROSING CHOLANGITIS, AND AUTOIMMUNE CHOLANGITIS
Sherlock, S. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70098-2 · Cited by 26
Update on Primary Biliary Cirrhosis
Heathcote, J. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/989486 · Cited by 24
Jones, D. E., James, O., & Bassendine, M. F. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70007-6 · Cited by 26
Self-citationPatterns of disease progression and incidence of complications in primary biliary cholangitis (PBC)
Janmohamed, A., & Trivedi, P. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.002 · Cited by 21
Liver disorders in the elderly
Floreani, A. (2009) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2009.10.005 · Cited by 21
Clinical management of autoimmune biliary diseases
Imam, M. H., Talwalkar, J. A., & Lindor, K. D. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.014 · Cited by 19
Emerging drugs for the treatment of Primary Biliary Cholangitis
Ali, A. H., Tabibian, J. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1150999 · Cited by 19
Voiculescu, M., Winkler, R. E., Moscovici, M., & Neuman, M. G. (2008) · PubMed · Cited by 18
Primary Biliary Cirrhosis and Hepatitis C Virus Infection
Floreani, A., Baragiotta, A. M., Leone, M. G., Baldo, V., & Naccarato, R. (2003) · The American Journal of Gastroenterology · doi:10.1016/j.amjgastroenterol.2003.08.021 · Cited by 18
New insights into autoimmune liver diseases
Kumagi, T., Alswat, K., Hirschfield, G. M., & Heathcote, J. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00366.x · Cited by 18
Primary biliary cirrhosis: From bench to bedside
Kouroumalis, E., & Notas, G. (2015) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v6.i3.32 · Cited by 21
Rising plasma nociceptin level during development of HCC: A case report
Horváth, A., Folhoffer, A., Lakatos, P. L., Halász, J., Íllyés, G., Schaff, Z., Hantos, M., Tekes, K., & Szalay, F. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i1.152 · Cited by 21
Zen, Y., Hübscher, S. G., & Nakanuma, Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00009-1 · Cited by 21
Jones, B. A., & Gores, G. J. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70017-9 · Cited by 16
Primary biliary cirrhosis: survival of a cohort followed for 10 years
Uddenfeldt, P., & Danielsson, A. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00733.x · Cited by 16
Khor, S., Ueno, K., Nishida, N., Kawashima, M., Kawai, Y., Aiba, Y., Hitomi, Y., Nagasaki, M., Nakamura, M., & Tokunaga, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1151502 · Cited by 14
Lazaridis, K. N., & Lindor, K. D. (1999) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-999-0051-0 · Cited by 12
Hosonuma, K., Sato, K., Yanagisawa, M., Kakizaki, S., Takagi, H., Hirato, J., & Mori, M. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/168012 · Cited by 15
Morimoto, T., Honda, G., Kawai, Y., Hirose, T., Nishio, T., Shinkura, N., Iimuro, Y., Yamamoto, N., Yamamoto, Y., Ikai, I., et al. (1999) · Surgery Today · doi:10.1007/bf02482993 · Cited by 11
Tumor-Associated Macrophages, Inflammation and Pathogenesis of Hepatocellular Carcinoma
Lewis, M. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000132 · Cited by 11
Chapter 2: Diagnosis and surveillance
(2010) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00655.x · Cited by 10
Schönau, J., Wester, A., Schattenberg, J. M., & Hagström, H. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.05.004 · Cited by 9
Biondetti, P., Fumarola, E. M., Ierardi, A. M., Coppola, A., Gorga, G., Maggi, L., Valconi, E., Angileri, S. A., & Carrafiello, G. (2020) · Medical Oncology · doi:10.1007/s12032-020-01365-x · Cited by 8
Metadata
- Authors
- Jones, D. E., Metcalf, J. V., Collier, J. D., Bassendine, M. F., & James, O. F.
- Affiliations
- Newcastle University (GB)
- Venue
- Hepatology
- Published
- 1997-11
- Volume
- 26
- Issue
- 5
- Pages
- 1138-1142
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2072040942
- Semantic Scholar
- f9368989eb2050966bd77bdcbaf009cd6c7ef523
- Cited by
- 161
- References
- 32
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 2 · 2018: 5 · 2017: 8 · 2016: 5 · 2015: 7 · 2014: 4 · 2013: 8 · 2012: 5
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6513 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Medical Research Council
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- hepatocellular carcinoma, primary biliary cirrhosis, HCC incidence, survival, Mayo risk score, sex differences, advanced liver disease, HCC screening, liver transplantation
- MeSH terms
- Aged, Aged, 80 and over, alpha-Fetoproteins, Female, Follow-Up Studies, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Biliary, Liver Neoplasms, Longitudinal Studies, Male, Middle Aged, Prognosis, Risk Factors, Cohort Studies, Incidence, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.